Article

Topical treatment improves corneal healing in pediatric patients with neurotrophic keratitis

Author(s):

In an e-poster presented at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., Abdelrahman M. Elhusseiny, MD, MSc, noted a research team found that cenegermin was effective for improving the corneal healing in these pediatric patients.

Topical cenegermin 0.002% ophthalmic solution (Oxervate, Dompé US) improved the corneal healing in cases ofpediatric neurotrophic keratopathy, according to Abdelrahman M. Elhusseiny, MD, MSc, an ophthalmology resident at the University of Arkansas for Medical Science in Little Rock.

This condition, which is rare, is the result of damage to the corneal nerves that can lead to decreased or loss of corneal sensation and impaired healing ability, according to a study by Elhusseiny and colleagues that was presented in an e-poster at the American Society of Cataract and Refractive Surgery’s2022 annual meeting in Washington, D.C.

According to the e-poster, the research team conducted a retrospective chart review of a series of pediatric patients with neurotrophic keratitis to determine their early experience using topical cenegermin 0.002% ophthalmic solution as a treatment.

In their study, all patientswere younger than 18 years and had been diagnosed with neurotrophic keratitis, and all had been treated with cenegermin ophthalmic solution between June 2018 and June 2021.

The data gathered during the chart review included the etiology of the neurotrophic keratitis, the patients’ ages at the time when topical cenegermin was started, ocular laterality, ethnicity, gender, history of a previous ocular therapy, the best-corrected visual acuity before and after therapy, the corneal condition before and after treatment, any treatment-related adverse events, associated ocular conditions, and the history of ocular surgeries, the investigators recounted.

Elhusseiny reported that 5 eyes of 5 pediatric patients were identified with neurotrophic keratitis during the study period. The children were a mean age of 4.8±1.9 years when the topical cenegermin therapy was started.

The mean time from NK diagnosis until the cenegermin drops were started was 4.5±4.1 months and the mean follow-up time was 12.2±10.1 months. In all 5 patients, after the therapy ended, there was marked improvement in epitheliopathy.

The best-corrected visual acuity was measurable in 4 eyes of 4 patients, and it improved from a mean of 0.15±0.14 to a mean of 0.41±0.31, a significant change (p = 0.2), Elhusseiny reported.

No adverse events were reported in relation to the cenegermin therapy.

The study conclusion was thatcenegermin was effective for improving the corneal healing in these pediatric patients.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.